High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial

Medicine (United States)

Volumn 95, Issue 28, 2016, Pages

  Li, Ru ^a   Zhao, Jin Xia ^b   Su, Yin ^a   He, Jing ^a   Chen, Li Na ^c   Gu, Fei ^d   Zhao, Cheng ^d   Deng, Xue Rong ^e   Zhou, Wei ^e   Hao, Yan Jie ^e   Xue, Yu ^f   Liu, Hua Xiang ^g   Zhao, Yi ^h   Zou, Qing Hua ⁱ   Liu, Xiang Yuan ^b   Zhu, Ping ^c   Sun, Ling Yun ^d   Zhang, Zhuo Li ^e   Zou, He Jian ^f   Li, Xing Fu ^g   Liu, Yi ^h   Fang, Yong Fei ⁱ   Keystone, Edward ^j   McInnes, Iain B ^k   Li, Zhan Guo ^a   more..

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b PEKING UNIVERSITY THIRD HOSPITAL   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^e PEKING UNIVERSITY FIRST HOSPITAL   (China)

^f FUDAN UNIVERSITY   (China)

^g SHANDONG UNIVERSITY   (China)

^h SICHUAN UNIVERSITY   (China)

ⁱ THIRD MILITARY MEDICAL UNIVERSITY   (China)

^j UNIVERSITY OF TORONTO   (Canada)

^k UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

DMARDs (synthetic); outcomes research; rheumatoid arthritis

Indexed keywords

CREATINE KINASE BB; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL DISEASE; ADULT; ALOPECIA; ANEMIA; ARTICLE; BLURRED VISION; BRAIN HEMORRHAGE; BRONCHITIS; COMBINATION DRUG THERAPY; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; DAS28; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FINGER; FOLLOW UP; HAND PARESTHESIA; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; LOADING DRUG DOSE; LONG TERM CARE; LUNG TUBERCULOSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MOUTH ULCER; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN PRURITUS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ARTHRITIS, RHEUMATOID; CHINA; CLINICAL TRIAL; RECURRENT DISEASE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; CHINA; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 84980009819     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003968     Document Type: Article

References (26)

1. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
2. O'Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013;369:307-18.
3. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
4. Landewé RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
5. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66: 1443-9.
6. van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexaterefractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012;379: 1712-20.
7. Keystone EC, Smolen J, van Riel P. Developing an effective treatment algorithm for rheumatoid arthritis. Rheumatology (Oxford) 2012;51 (suppl 5):v48-54.
8. ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebocontrolled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996;347:347-52.
9. Klarenbeek NB, van der Kooij SM, Güler-Yüksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011;70:315-9.
10. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
11. Fransen J, Creemers MC, van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2000;43:1252-5.
12. Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:143-50.
13. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
14. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
15. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
16. Curtis JR, Yang S, Chen L, et al. Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. Ann Rheum Dis 2012;71:206-12.
17. Hyrich KL, Watson KD, Silman AJ, et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006;45:1558-65.
18. Anderson JJ, Wells G, Verhoeven AC, et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
19. Saevarsdottir S, Wallin H, Seddighzadeh M, et al. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis 2011;70:469-75.
20. Curtis JR, McVie T, Mikuls TR, et al. Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR trial. J Rheumatol 2013;40:572-8.
21. Scirè CA, Montecucco C, Codullo V, et al. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology (Oxford) 2009;48:1092-7.
22. Saleem B, Brown AK, Quinn M, et al. Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. Ann Rheum Dis 2012;71:1316-21.
23. Singer O, Gibofsky A. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011? Curr Opin Rheumatol 2011;23: 288-92.
24. Narváez J, Díaz-Torné C, Ruiz JM, et al. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2011;41: 401-5.
25. Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001;44:1984-92.
26. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124-34.